CIRRH
MCID: LVR012
MIFTS: 60

Liver Cirrhosis (CIRRH)

Categories: Gastrointestinal diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Liver Cirrhosis

MalaCards integrated aliases for Liver Cirrhosis:

Name: Liver Cirrhosis 11 75 53 43 14 36 71 33
Cirrhosis 11 73 53 41 14 38 71 75
Cirrhosis of Liver 11 28 5 16
Cirrhosis, Cryptogenic 71
Cryptogenic Cirrhosis 73
Cirrhosis Nos 33
Cirrh 73

Classifications:



External Ids:

Disease Ontology 11 DOID:5082
MeSH 43 D008103
NCIt 49 C2951
SNOMED-CT 68 19943007
ICD11 33 1781315693
UMLS 71 C0023890 C0267809 C1623038

Summaries for Liver Cirrhosis

MedlinePlus: 41 Cirrhosis is scarring of the liver. Scar tissue forms because of injury or long-term disease. Scar tissue cannot do what healthy liver tissue does - make protein, help fight infections, clean the blood, help digest food and store energy. Cirrhosis can lead to : Easy bruising or bleeding, or nosebleeds Swelling of the abdomen or legs Extra sensitivity to medicines High blood pressure in the vein entering the liver Enlarged veins called varices in the esophagus and stomach. Varices can bleed suddenly. Kidney failure Jaundice Severe itching Gallstones A small number of people with cirrhosis get liver cancer. Your doctor will diagnose cirrhosis with blood tests, imaging tests, or a biopsy. Cirrhosis has many causes. In the United States, the most common causes are chronic alcoholism and hepatitis. Nothing will make the scar tissue disappear, but treating the cause can keep it from getting worse. If too much scar tissue forms, you may need to consider a liver transplant. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary: Liver Cirrhosis, also known as cirrhosis, is related to alcoholic liver cirrhosis and primary biliary cholangitis, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Liver Cirrhosis is FARSB (Phenylalanyl-TRNA Synthetase Subunit Beta), and among its related pathways/superpathways are Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) and Lung fibrosis. The drugs Carvedilol and Fentanyl have been mentioned in the context of this disorder. Affiliated tissues include Bone and Blood.

UniProtKB/Swiss-Prot: 73 A liver disease characterized by severe panlobular liver-cell swelling with Mallory body formation, prominent pericellular fibrosis, and marked deposits of copper. Clinical features include abdomen swelling, jaundice and pulmonary hypertension.

Wikipedia: 75 Cirrhosis, also known as liver cirrhosis or hepatic cirrhosis, and end-stage liver disease, is the... more...

Related Diseases for Liver Cirrhosis

Diseases related to Liver Cirrhosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1933)
# Related Disease Score Top Affiliating Genes
1 alcoholic liver cirrhosis 33.5 HGF HFE GPT GGT1 F2 CYP2E1
2 primary biliary cholangitis 33.1 SLC17A5 SERPINA1 GPT GGT1 F2 ALB
3 hepatitis 32.8 SLC17A5 SERPINA1 IFNA1 GPT GGT1 F2
4 alcohol dependence 32.5 SLC17A5 GPT GGT1 CYP2E1 ALB
5 portal hypertension 32.5 SLC17A5 REN GPT GGT1 F2 EDN1
6 hepatic encephalopathy 32.5 SLC17A5 GPT F2 ALB
7 budd-chiari syndrome 32.5 GPT F2 ALB AFP
8 cholangitis, primary sclerosing 32.4 SERPINA1 GPT GGT1 F2 ALB AFP
9 esophageal varix 32.4 SERPINA1 GPT F2 ALB AFP
10 hepatitis b 32.2 SLC17A5 IFNA1 GPT GGT1 F2 ALB
11 portal vein thrombosis 32.1 GPT F2 ALB AFP
12 alcohol use disorder 32.1 SLC17A5 HFE GPT GGT1 F2 CYP2E1
13 hepatorenal syndrome 32.1 REN GPT F2 EDN1 ALB AFP
14 non-alcoholic fatty liver disease 32.0 HFE GPT GGT1 CYP2E1 ALB
15 viral hepatitis 32.0 SLC17A5 SERPINA1 IFNA1 HFE GPT GGT1
16 hypersplenism 31.9 GPT F2 ALB AFP
17 thrombocytopenia 31.8 SLC17A5 IFNA1 GPT GGT1 F2 EDN1
18 cholestasis 31.8 SLC17A5 SERPINA1 GPT GGT1 F2
19 non-alcoholic steatohepatitis 31.8 GPT CYP2E1 ALB AFP
20 hepatitis c 31.8 SLC17A5 IFNA1 HOTAIR HFE GPT GGT1
21 peptic ulcer disease 31.8 GPT F2 ALB
22 cholangitis 31.7 GPT GGT1 F2 ALB
23 autoimmune hepatitis 31.7 SLC17A5 GPT GGT1 F2 ALB
24 hemochromatosis, type 1 31.7 SERPINA1 HFE GPT F2 ALB AFP
25 hepatic coma 31.6 HGF GPT F2 ALB AFP
26 cholelithiasis 31.6 SERPINA1 GPT ALB
27 wilson disease 31.6 SERPINA1 HFE GPT F2 ALB
28 alpha-1-antitrypsin deficiency 31.5 SERPINA1 HFE GPT F2 ALB AFP
29 alcoholic hepatitis 31.5 SLC17A5 HGF GPT GGT1 F2 CYP2E1
30 acute kidney failure 31.5 REN HGF GPT F2 ALB
31 liver disease 31.5 SLC17A5 SERPINA1 MEG3 IFNA1 HGF HFE
32 kidney disease 31.5 REN HGF HFE GGT1 F2 EDN1
33 cholecystitis 31.5 GPT F2 ALB
34 urinary tract infection 31.5 REN GPT F2 ALB
35 pancreatitis 31.5 SERPINA1 GGT1 CYP2E1 ALB
36 fatty liver disease 31.5 MALAT1 HFE GPT GGT1 CYP2E1 AFP
37 deficiency anemia 31.4 REN IFNA1 HFE GPT F2 ALB
38 schistosomiasis 31.4 GPT F2 ALB
39 bilirubin metabolic disorder 31.4 SLC17A5 SERPINA1 GPT GGT1 F2 CYP2E1
40 sclerosing cholangitis 31.4 SERPINA1 GPT F2 ALB AFP
41 obstructive jaundice 31.4 SLC17A5 GPT GGT1 F2 ALB AFP
42 respiratory failure 31.3 SERPINA1 REN IFNA1 GPT F2 ALB
43 pleural empyema 31.3 GPT F2 ALB
44 nephrotic syndrome 31.3 SERPINA1 REN F2 EDN1 ALB
45 inguinal hernia 31.2 GPT F2 ALB AFP
46 acute liver failure 31.2 HGF F2
47 acute kidney tubular necrosis 31.2 REN HGF GPT ALB
48 hepatitis a 31.2 SERPINA1 IFNA1 GPT F2 ALB AFP
49 choledocholithiasis 31.2 SLC17A5 GPT GGT1 F2 ALB
50 active peptic ulcer disease 31.2 GPT F2 ALB

Graphical network of the top 20 diseases related to Liver Cirrhosis:



Diseases related to Liver Cirrhosis

Symptoms & Phenotypes for Liver Cirrhosis

UMLS symptoms related to Liver Cirrhosis:


nausea and vomiting; constipation; abdominal pain; diarrhea; hepatosplenomegaly; dyspepsia; icterus; heartburn; gastrointestinal gas

Drugs & Therapeutics for Liver Cirrhosis

Drugs for Liver Cirrhosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 624)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
2
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
3
Tranexamic acid Approved Phase 4 1197-18-8 5526
4
Magnesium oxide Approved Phase 4 1309-48-4 14792
5
Insulin glulisine Approved Phase 4 207748-29-6
6
Insulin glargine Approved Phase 4 160337-95-1 118984454
7
Grazoprevir Approved Phase 4 1350514-68-9 72535808 44603531
8
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
9
Azithromycin Approved Phase 4 83905-01-5 447043
10
Imipenem Approved Phase 4 74431-23-5, 64221-86-9 104838
11
Clavulanic acid Approved, Vet_approved Phase 4 58001-44-8 5280980
12
Acetic acid Approved Phase 4 64-19-7 176
13
Zinc cation Approved, Experimental, Investigational Phase 4 7440-66-6, 23713-49-7 32051
14
Abatacept Approved Phase 4 332348-12-6
15
Colchicine Approved Phase 4 64-86-8 2833 6167
16
Peginterferon alfa-2b Approved Phase 4 215647-85-1, 99210-65-8
17
Ribavirin Approved Phase 4 36791-04-5 37542
18
Losartan Approved Phase 4 114798-26-4 3961
19
Meloxicam Approved, Vet_approved Phase 4 71125-38-7 54677470 5281106
20
Ibandronate Approved, Investigational Phase 4 114084-78-5 60852
21
Telbivudine Approved, Investigational Phase 4 3424-98-4 159269
22
Somatostatin Approved, Investigational Phase 4 38916-34-6, 51110-01-1 53481605 16129706
23
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
24
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456 5824
25
Atropine Approved, Vet_approved Phase 4 101-31-5, 5908-99-6, 51-55-8 3661 154417 174174
26
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
27
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4
28
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
29
Cefoxitin Approved Phase 4 35607-66-0 441199
30
Cefotaxime Approved Phase 4 63527-52-6 5742673 456256
31
Adefovir dipivoxil Approved, Investigational Phase 4 142340-99-6 60871
32
Simeprevir Approved Phase 4 923604-59-5 66811198 24873435 66576988
33
Nadolol Approved Phase 4 42200-33-9 39147
34
Basiliximab Approved, Investigational Phase 4 179045-86-4
35
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
36
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
37
Ledipasvir Approved Phase 4 1256388-51-8 67505836
38
Canrenoic acid Approved, Withdrawn Phase 4 4138-96-9 4872
39
Cefoperazone Approved, Investigational Phase 4 62893-19-0 44185 44187
40
Teicoplanin Approved, Investigational Phase 4 61036-62-2 16170201
41
Tinidazole Approved, Investigational Phase 4 19387-91-8 5479
42
Methylene blue Approved, Investigational Phase 4 61-73-4 6099
43
Ropinirole Approved, Investigational Phase 4 91374-21-9 5095
44
Insulin lispro Approved Phase 4 133107-64-9 16132438
45
Isosorbide dinitrate Approved, Investigational Phase 4 87-33-2 3780 6883
46
Isosorbide Approved, Investigational Phase 4 652-67-5 99937 12597
47
Prazosin Approved Phase 4 19216-56-9 4893
48
Meperidine Approved Phase 4 57-42-1 4058
49
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
50
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1

Interventional clinical trials:

(show top 50) (show all 1802)
# Name Status NCT ID Phase Drugs
1 Losartan in the Prevention of Sodium Retention and Ascites in Liver Cirrhosis - a Prospective Randomized Long-Term Study Unknown status NCT00239096 Phase 4 losartan (drug)
2 A Multi-Center Study to Assess the Efficacy and Safety of Traditional Chinese Medicine Combined With Entecavir for Patients With Refractory Liver Fibrosis in Liver Cirrhosis Due to HBV Unknown status NCT02241616 Phase 4 Entecavir+Fuzheng Huayu+TCM Granule
3 A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study to Assess the Efficacy and Safety of Fuzheng Huayu Combined With Entecavir in Liver Cirrhosis Patients Due to Hepatitis B Virus Unknown status NCT02241590 Phase 4 Entecavir + Placebo;Entecavir + Fuzheng Huayu Tablet
4 Telbivudine Renoprotective Effect in Patients With HBV-related Liver Cirrhosis Unknown status NCT01693679 Phase 4 Telbivudine, Lamivudine, Adefovir ,Enecavir
5 Therapeutic Efficacy of Oral L-Ornithine-L-Aspartate on Liver Cirrhosis and Minimal Encephalopathy: a Single Center Placebo Control Double Blind Study Unknown status NCT00896831 Phase 4 L-ornithine-L-aspartate;placebo
6 Randomized Controlled Trial Comparing Propranolol, Endoscopic Banding Ligation, and Combined Treatment to Prevent First Variceal Hemorrhage in Patients With Liver Cirrhosis Unknown status NCT00965900 Phase 4 Propranolol
7 Metformin Experience on Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis Unknown status NCT02470546 Phase 4 Metformin;Placebo
8 Effect of Vardenafil on Erectile Dysfunction and Portal Hemodynamics in Patients With Liver Cirrhosis Unknown status NCT02344823 Phase 4 Vardenafil;Placebo intake once daily
9 Clinical Study of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B Unknown status NCT01380951 Phase 4 telbivudine
10 Telbivudine Renoprotective Effect in Patients With the HBV-related Liver Cirrhosis: a Randomized Controlled Trial Unknown status NCT01799486 Phase 4 Telbivudine;Enecavir;Adefovir
11 Primary Prophylaxis of High-risk Esophageal Gastric Variceal Bleeding Comparing Carvedilol and Endoscopic Therapy: A Multicenter Randomized Controlled Trial Unknown status NCT02695732 Phase 4 Carvedilol
12 Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis:A Zelen-design Multicenter Randomized Controlled Trial Unknown status NCT02630095 Phase 4 Nadroparin Calcium and Warfarin
13 Hemodynamic Profile of Terlipressin and Octreotide in Patients With Cirrhosis and Portal Hypertension. A Randomised, Single Blinded Clinical Trial. Unknown status NCT04353193 Phase 4 Terlipressin;Octreotide
14 Magnesium Deficiency in Cirrhotic Patients Unknown status NCT01894867 Phase 4
15 The Effect of Carvedilol Vs Propranolol in Patients With Cirrhosis Related Esophagogastric Varices After Multiple Endoscopic Treatments For Secondary Prophylaxis:A Randomized Controlled Trial Unknown status NCT02385422 Phase 4 Carvedilol;Propranolol
16 A Randomized Tril of Endoscopic Cyanoacrylate Obliteration vs. Nadolol Unknown status NCT00567216 Phase 4 Nadolol
17 A Zelen-design Randomized Controlled Trial of the Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis Unknown status NCT02398357 Phase 4 Nadroparin Calcium and Warfarin
18 Insulin Therapy in the Inpatient Management of Cirrhotic Patients With Type 2 Diabetes Unknown status NCT01143948 Phase 4 Glargine & Glulisine;Regular insulin;NPH & regular insulin
19 Effect of Betablocker or Aldosterone Antagonist Therapy on Oxygenation, Peripheral and Cardiac Hemodynamics and Humoral Systems Unknown status NCT00332904 Phase 4 propranolol;spironolactone
20 Endoscopic Treatment Alone Versus Combined Propranolol and Endoscopic Treatment of Acute Variceal Hemorrhage in Patients With HCC:a Randomized Trial Unknown status NCT01298284 Phase 4 propranolol
21 Prevention of Progression of Portal Hypertension in Compensated Cirrhosis Using Selective Hepatic Vasodilators. A Double-blind, Multicenter,Randomized Controlled Trial Unknown status NCT01282398 Phase 4 Simvastatin;placebo
22 Hemodynamic Effect of the Combination of Simvastatin With Non-cardioselective Beta Blockers in Patients With Cirrhosis and Clinically Significant Portal Hypertension Unknown status NCT01282385 Phase 4 Simvastatin;placebo
23 Branched-chain Amino Acid (BCAA) on Progression of Advanced Liver Disease (BRAVE): Korean Nation-wide Multicenter Retrospective and Prospective Observational Cohort Study Unknown status NCT02837302 Phase 4 Livact
24 A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial Unknown status NCT01965418 Phase 4 Fufang Biejia Ruangan Tablet;Placebo
25 Prospective, Multicenter, Randomized, and Comparative Clinical Trials to Compare the Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes Unknown status NCT04584242 Phase 4 gluconon tab 15mg;suganon tab 5mg
26 The Effect of HVPG-Guided Individualized Therapy in Patients With Cirrhosis Related Esophagogastric Variceal Hemorrhage For Secondary Prophylaxis:A Randomized Controlled Trial Unknown status NCT02638415 Phase 4 Carvedilol
27 Entecavir for Patients With Decompensated HBV-Related Cirrhosis:a Prospective Randomized Controlled Trial Unknown status NCT00663182 Phase 4 Entecavir
28 A Randomized Controlled Trial of 18-22mg/kg/d Ursodeoxycholic in Refractory Primary Biliary Cholangitis Unknown status NCT03345589 Phase 4 18-22mg/kg/d Ursodeoxycholic;13-15mg/kg/d Ursodeoxycholic
29 Efficacy and Safety of Switching to Tenofovir Alafenamide for Chronic Hepatitis B Patients With Advanced Fibrosis and Partial Virologic Responses to Oral Nucleos(t)Ide Analogues Unknown status NCT03798119 Phase 4 Tenofovir Alafenamide
30 Rifaximin Predicts the Complications of Decompensated Cirrhosis: a Randomized Controlled Trial Unknown status NCT02074280 Phase 4 rifaximin
31 Albumin Infusion Effects in Mortality in Patients With Cirrhosis and Hepatic Encephalopathy Unknown status NCT02401490 Phase 4 Human albumin;Placebo
32 The Employing of the Bio-Hep-B PreS1/PreS2/S Hepatitis B Virus (HBV) Vaccine in New Born Babies From HBV Positive Palestinian Mothers Unknown status NCT01133184 Phase 4
33 Bacterial Infections Associated With Healthcare (Healthcare-Associated) in Hospitalized Cirrhotic Patients: Randomized Study of Use of Traditional Empirical Antibiotic Therapy and Second-line Targeted at Multi-resistant Bacteria Unknown status NCT01820026 Phase 4 Imipenem;Vancomycin;azithromycin;Cefotaxime;Amoxicillin
34 A Randomised Trial Comparing Entacavir and Tenofovir in Patients With HBV Decompensated Cirrhosis Unknown status NCT02238860 Phase 4 Entacavir;Tenofovir
35 Rifaximin Reduces the Complications of Decompensated Cirrhosis Unknown status NCT02190357 Phase 4 Rifaximin
36 Development of an Imaging Biomarker for Hepatic Fibrosis Using Gadoxetate Disodium Unknown status NCT01783314 Phase 4
37 Emtricitabine Plus Adefovir Dipivoxil for Naive Chinese HBV Related Cirrhosis Patients Unknown status NCT02327689 Phase 4 Emtricitabine plus adefovir dipivoxil
38 Trial of Ablation of Small Hepatocellular Carcinomas in Patients of Cirrhosis Unknown status NCT01438437 Phase 4
39 Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis: An Open Label, Randomized Controlled Trial of Lactulose, Probiotics and No-therapy Unknown status NCT01178372 Phase 4 Lactulose;Probiotics(VSL#3)
40 Primary Prophylaxis of Hepatic Encephalopathy in Patients With Cirrhosis: an Open Labeled Randomized Controlled Trial of Lactulose Versus no Lactulose Unknown status NCT01175538 Phase 4 Lactulose
41 Assessment of Coagulation Abnormalities in Acute on Chronic Liver Failure Patients Using Thromboelastography Unknown status NCT02757170 Phase 4
42 The Effect of Branched-chain Amino Acid on the Improvement of Serum Albumin Level in Cirrhotic Patients With Ascites: A Multi-center, Randomized, Double-blind, Placebo-controlled, Investigator Initiated Clinical Trial Unknown status NCT02755701 Phase 4 Branched-chain Amino Acid;Placebo
43 Safety and Fibrosis Improvement of Grazoprevir and Elbasvir for HCV GT1 and GT6 With or Without HIV Unknown status NCT03037151 Phase 4 Grazaoprevir/Elbasavir;Grazaoprevir/Elbasavir/RBV
44 Impact of Nonselective Beta-blocker on Acute Kidney Injury in Cirrhotic Patients With Esophageal Varices Unknown status NCT04074473 Phase 4 propranolol
45 A Randomized Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis Unknown status NCT00761098 Phase 4 Standard Care;Experimental
46 Efficacy and Safety of Early Administration of Tranexamic Acid in Cirrhotic Patients Presenting With Acute Upper Gastrointestinal Bleeding: a Multicenter, Randomized, Double Blind, Placebo-controlled Trial (Modified by amendment1) Unknown status NCT03023189 Phase 4 Tranexamic acid;Placebo
47 Randomized and Controlled Clinical Trial of Transfusional Requirements in Patients With Acute Gastrointestinal Bleeding. Unknown status NCT00414713 Phase 4
48 RCT Comparing the Efficacies of Endoscopic Band Ligation (EBL) and Combined Treatment of Beta-blocker and EBL for the Prevention of Esophageal Variceal Rebleeding in Patients With Previous Endoscopic Variceal Treatment Unknown status NCT00966082 Phase 4
49 Propofol and Fentanyl Versus Midazolam and Fentanyl for Sedation During Diagnostic or Therapeutic Gastrointestinal Endoscopy in Cirrhotic Patients Unknown status NCT00906139 Phase 4 Propofol;Midazolam;Fentanyl
50 RCT Comparing the Efficacies of Endoscopic Variceal Ligation (EBL) and Combined Treatment of Beta-blocker and EBL for the Prevention of Esophageal Variceal Rebleeding Unknown status NCT00966121 Phase 4

Search NIH Clinical Center for Liver Cirrhosis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Bumetanide
Ethacrynate Sodium
Ethacrynic Acid
Furosemide
Milk thistle extract
torsemide

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Liver Cirrhosis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Liver Cirrhosis:
Autologous bone marrow-derived mesenchymal stem cells for liver cirhosis
Autologous bone marrow-derived stem cells for treatment of liver cirrhosis
Autologous hematopoietic stem cells for treatment of end-stage chronic liver disease
Bone marrow-derived endothelial progenitor cells for advanced liver cirrhosis
Bone marrow-derived mesenchymal stem cells for treatment of cirrhosis-related refractory ascites
Bone marrow-derived mesenchymal stem cells for treatment of liver cirrhosis
Hepatocyte transplantation for treatment of liver failure and inherited metabolic diseases
Mesenchymal stem cells for liver cirrhosis
NU215-01, human umbilical cord mesenchymal stem cells for treatment of liver cirrhosis
Peripheral blood-derived CD34+ or mononuclear cells for liver cirrhosis
StempeucelLC, mesenchymal stem cells for liver cirrhosis
Umbilical cord-derived mesenchymal stem cells for treatment of liver cirrhosis
Embryonic/Adult Cultured Cells Related to Liver Cirrhosis:
Bone marrow-derived mesenchymal stem cells (family) PMIDs: 22121493 21771778
Peripheral blood-derived hematopoietic stem cells PMIDs: 20587151
Bone marrow-derived endothelial progenitor cells (family)
Hepatocytes
Umbilical cord-derived mesenchymal stem cells
Peripheral blood-derived hematopoietic stem cells (family)
Peripheral blood-derived mesenchymal stem cells (family)
Bone marrow-derived mesenchymal stem cells (Stempeucel) PMIDs: 18720444
Umbilical cord-derived mesenchymal stem cells (family)

Cochrane evidence based reviews: liver cirrhosis

Genetic Tests for Liver Cirrhosis

Genetic tests related to Liver Cirrhosis:

# Genetic test Affiliating Genes
1 Cirrhosis of Liver 28

Anatomical Context for Liver Cirrhosis

Organs/tissues related to Liver Cirrhosis:

MalaCards : Liver, Bone Marrow, Kidney, Bone, Spleen, Endothelial, Skin
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Liver Cirrhosis:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate
2 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
3 Liver Sinusoids Hepatic Stellate Cells Affected by disease
4 Liver Liver Lobule Hepatocytes Affected by disease
5 Blood Cord Blood Mesenchymal Stem Cells Potential therapeutic candidate
6 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate

Publications for Liver Cirrhosis

Articles related to Liver Cirrhosis:

(show top 50) (show all 50816)
# Title Authors PMID Year
1
Fibrosis-4 index efficiently predicts chronic hepatitis and liver cirrhosis development based on a large-scale data of general population in Japan. 62 41
36437271 2022
2
Global, regional, and national burden of cirrhosis and other chronic liver diseases due to alcohol use, 1990-2019: a systematic analysis for the Global Burden of Disease study 2019. 62 41
36418998 2022
3
The role of hepatic microenvironment in hepatic fibrosis development. 41
36399108 2022
4
The potential role of insulin-like growth factor 1, insulin-like growth factor binding protein 3 and bone mineral density in patients with chronic hepatitis C virus in Cairo, Egypt. 53 62
20189618 2010
5
Increased expression of urotensin II and GPR14 in patients with cirrhosis and portal hypertension. 53 62
20428787 2010
6
Relationship between the expression of IP-10 and IP-10 mRNA in peripheral blood and HBV DNA level in patients with cirrhosis. 53 62
20525556 2010
7
Expression of urotensin II and its receptor in human liver cirrhosis and fulminant hepatic failure. 53 62
19582578 2010
8
Correlation of liver stiffness and histological features in healthy persons and in patients with occult hepatitis B, chronic active hepatitis B, or hepatitis B cirrhosis. 53 62
19920809 2010
9
Splanchnic concentrations and postprandial release of visceral adipokines. 53 62
19913846 2010
10
Hemodynamic effects of chronic smoking in liver cirrhosis: a role for adrenomedullin. 53 62
20216319 2010
11
Influence of transforming growth factor-beta1 gene polymorphism at codon 10 on the development of cirrhosis in chronic hepatitis B virus carriers. 53 62
20357999 2010
12
Hepatic osteodystrophy and liver cirrhosis. 53 62
20355242 2010
13
Relationship and clinical significance of TGF-beta1 expression with Treg cell infiltration in hepatocellular carcinoma. 53 62
20346216 2010
14
Aquaporin-2 urinary excretion in cirrhosis: relationship to vasopressin and nitric oxide. 53 62
19495975 2010
15
Clinical trial: short-term effects of combination of satavaptan, a selective vasopressin V2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatraemia--a randomized, double-blind, placebo-controlled study. 53 62
20102356 2010
16
Significance of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in chronic hepatitis C patients. 53 62
20350877 2010
17
Alpha-fetoprotein gene polymorphisms and risk of HCC and cirrhosis. 53 62
19968979 2010
18
Utilization of platelet count spleen diameter ratio in predicting the presence of esophageal varices in patients with cirrhosis. 53 62
19593164 2010
19
Impact factors for microinvasion in patients with hepatocellular carcinoma: possible application to the definition of clinical tumor volume. 53 62
19406586 2010
20
Impact of antithrombin III concentrates on portal vein thrombosis after splenectomy in patients with liver cirrhosis and hypersplenism. 53 62
19864937 2010
21
Usefulness of non-invasive markers for predicting liver cirrhosis in patients with chronic hepatitis B. 53 62
19793171 2010
22
Hepatitis B virus load in serum does not reflect histologic activity in patients with decompensated cirrhosis. 53 62
19804841 2010
23
Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. 53 62
19877168 2010
24
Increased bactericidal/permeability increasing protein in patients with cirrhosis. 53 62
19765220 2010
25
[Relationship between quality of life and basic syndromes of traditional Chinese medicine in patients with posthepatitic cirrhosis]. 53 62
20082755 2010
26
Potential conditions causing impairment of selective hepatobiliary enhancement of gadobenate dimeglumine-enhanced delayed magnetic resonance imaging. 53 62
20118733 2010
27
[Expressions of MDM2 and MMP-7 in normal liver, cirrhosis, hepatocellular carcinoma tissues]. 53 62
20128976 2010
28
Bone mineral density and serum levels of soluble tumor necrosis factors, estradiol, and osteoprotegerin in postmenopausal women with cirrhosis after viral hepatitis. 53 62
19897681 2009
29
[Monitoring patients with chronic hepatitis during and after therapy]. 53 62
20198895 2009
30
Severe sepsis in cirrhosis. 53 62
19885876 2009
31
Resolution of preoperative portal vein thrombosis after administration of antithrombin III in living donor liver transplantation: case report. 53 62
19917415 2009
32
IkappaBalpha gene promoter polymorphisms are associated with hepatocarcinogenesis in patients infected with hepatitis B virus genotype C. 53 62
19797428 2009
33
Comparison of the effect of BCAA granules on between decompensated and compensated cirrhosis. 53 62
20214224 2009
34
A novel nonsynonymous variant of matrix metalloproteinase-7 confers risk of liver cirrhosis. 53 62
19676133 2009
35
Correlation of routinely used coagulation parameters and presence of portal vein thrombosis in patients with liver cirrhosis. 53 62
19619258 2009
36
Validation of connective tissue growth factor (CTGF/CCN2) and its gene polymorphisms as noninvasive biomarkers for the assessment of liver fibrosis. 53 62
19243500 2009
37
Endothelial to mesenchymal transition via transforming growth factor-beta1/Smad activation is associated with portal venous stenosis in idiopathic portal hypertension. 53 62
19608867 2009
38
Twenty-year survivors after resection for hepatocellular carcinoma-analysis of 53 cases. 53 62
19294419 2009
39
Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality. 53 62
19642174 2009
40
[Analysis of prognostic factors for patients with acute-on-chronic liver failure]. 53 62
19719920 2009
41
Prediction of the prognosis of patients with acute-on-chronic hepatitis B liver failure using the model for end-stage liver disease scoring system and a novel logistic regression model. 53 62
19413694 2009
42
[Comparison of the serum proteomes of pathological stages during hepatocarcinogenesis]. 53 62
19912687 2009
43
Perioperative factors affecting long-term outcomes of 473 consecutive patients undergoing hepatectomy for hepatocellular carcinoma. 53 62
19365625 2009
44
Cytokine evaluation in liver cirrhosis and hepatocellular carcinoma. 53 62
19760951 2009
45
Plasma proteasome level is a reliable early marker of malignant transformation of liver cirrhosis. 53 62
19201777 2009
46
Milder liver cirrhosis and loss of serum HBeAg do not imply lower risk for hepatocellular carcinoma development in HBV-related cirrhosis. 53 62
19478697 2009
47
Effectiveness of combination therapy of splenectomy and long-term interferon in patients with hepatitis C virus-related cirrhosis and thrombocytopenia. 53 62
19207581 2009
48
Altered basal and postprandial plasma melatonin, gastrin, ghrelin, leptin and insulin in patients with liver cirrhosis and portal hypertension without and with oral administration of melatonin or tryptophan. 53 62
19552764 2009
49
Abundance of immunologically active alanine aminotransferase in sera of liver cirrhosis and hepatocellular carcinoma patients. 53 62
19264859 2009
50
Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis. 53 62
19220736 2009

Variations for Liver Cirrhosis

ClinVar genetic disease variations for Liver Cirrhosis:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 FARSB NM_005687.5(FARSB):c.1381A>C (p.Thr461Pro) SNV Pathogenic
545642 rs1396171148 GRCh37: 2:223478611-223478611
GRCh38: 2:222613892-222613892
2 FARSB NM_005687.5(FARSB):c.784A>G (p.Lys262Glu) SNV Pathogenic
545655 rs1553554543 GRCh37: 2:223496325-223496325
GRCh38: 2:222631606-222631606
3 FARSB NM_005687.5(FARSB):c.1202G>A (p.Arg401Gln) SNV Pathogenic
545664 rs1553553086 GRCh37: 2:223488418-223488418
GRCh38: 2:222623699-222623699
4 FARSB NM_005687.5(FARSB):c.755T>C (p.Phe252Ser) SNV Pathogenic
545694 rs1466642025 GRCh37: 2:223496354-223496354
GRCh38: 2:222631635-222631635
5 FARSB NM_005687.5(FARSB):c.226T>C (p.Cys76Arg) SNV Pathogenic
545695 rs1419129874 GRCh37: 2:223507613-223507613
GRCh38: 2:222642894-222642894

Copy number variations for Liver Cirrhosis from CNVD:

6
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 210504 6 30400000 36600000 Copy number C4B Liver cirrhosis

Expression for Liver Cirrhosis

Search GEO for disease gene expression data for Liver Cirrhosis.

Pathways for Liver Cirrhosis

GO Terms for Liver Cirrhosis

Cellular components related to Liver Cirrhosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.64 SERPINA1 REN IFNA1 HGF HFE GPT

Biological processes related to Liver Cirrhosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to ozone GO:0010193 8.92 EDN1 CYP2E1

Sources for Liver Cirrhosis

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....